Day: September 16, 2025

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) — Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has completed patient enrollment in its Phase II clinical trial of MCS‑8, an investigational drug candidate for prostate cancer prevention (PCP), with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement. The randomized, placebo-controlled trial is being conducted across 20 hospitals in Taiwan, with the participation of more than 130 urologists. “We are...

Not for release to US wire services or distribution in the United States PERTH, Australia, Sept. 16, 2025 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (Paladin or the Company) announces the successful completion of its fully underwritten equity raising, comprising (i) an ~A$231 million ASX institutional placement of new Paladin fully paid ordinary shares (Shares) (ASX Placement), (ii) a Canadian “bought deal” private placement to raise C$30 million (~A$33 million) pursuant to the Listed Issuer Financing Exemption (as defined herein) (TSX Bought Deal), and (iii) a fully underwritten sale of ~A$36 million of existing Shares issued and subsequently acquired as a result of the acquisition of Fission Uranium Corp. (Fission) (Treasury Share Sale), to raise a total amount of A$300 million (together, the Offer).1 As...

Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchases of crypto tokens under its recently announced cryptocurrency treasury strategy targeting multi-chain asset growth. The Company’s acquisition of Ethereum (ETH) and Solana (SOL) tokens marks the first step toward incorporating cryptocurrency into its treasury holdings and lays the foundation for Silo’s broader blockchain and real world asset (RWA) tokenization initiatives. The investment underscores the Company’s belief in the long-term value of digital assets and the potential of underlying...

LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus (srSLE). Abstract: 2458Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients with severe, refractory systemic lupus erythematosus (srSLE): preliminary...

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized a major commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the process of securing formulary access with health plans covering more than 100 million lives for ArbliTM (losartan potassium)...

TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (“Allied”) (TSX: “AP.UN”) today provided an update with respect to non-core property sales. “We initiated the sale process last year to fund the acquisition of larger than expected interests in 400 West Georgia, 19 Duncan and Calgary House,” said Michael Emory, Founder & Executive Chair. “We’ve continued this year with the immediate objective of improving access to the debt capital markets and the longer-term objective of serving knowledge-based organizations in Canada’s major cities ever-better and more profitably.” Non-Core Property Sales In 2024, Allied sold seven non-core properties (four in Montréal, one in Ottawa, one in Toronto and one in Calgary) for aggregate proceeds of $252 million. To date in 2025,...